Phase II randomized, double blind, placebo controlled, clinical trial of safety and immunogenicity of an inactivated SARS-CoV-2 vaccine FAKHRAVAC in adults aged 18–70 years

Fatemeh Gholami,Ramin Hamidi Farahani,Ahmad Karimi Rahjerdi,Mohammadreza Ahi,Ali Sheidaei,Kimiya Gohari,Zahra Rahimi,Akram Ansarifar,Pouria Basiri,Milad Moradi,Arash Jahangiri,Kosar Naderi,Soheil Ghasemi,Pezhman Khatami,Mohsen Honari,Samane Khodaverdloo,Mohammad Shooshtari,Hajar Mehr Azin,Sohrab Moradi,Batool Shafaghi,Hossein Allahyari,Arina Monazah,Ali Khodaei Poor,Zahra Taghva,Hooman Bakhshande,Mohammad Karimi Nia,Masoud Solaymani Dodaran,Mohsen Forooghizade
DOI: https://doi.org/10.1186/s12879-023-08079-1
IF: 3.7
2023-02-26
BMC Infectious Diseases
Abstract:The FAKHRAVAC®, an inactivated SARS-CoV-2 vaccine, was assessed for safety and immunogenicity in a phase II trial.
infectious diseases
What problem does this paper attempt to address?